Form 4: MacroGenics Executive Jeffrey Stuart Peters Reports Stock Transactions
SEC Form 4 Filing
Senior VP and General Counsel of MacroGenics, Jeffrey Stuart Peters, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.
Summary
- On April 4, 2024, Jeffrey Stuart Peters, Senior VP and General Counsel of MacroGenics Inc., executed transactions involving the company's common stock.
- Peters exercised options to acquire 42,500 shares of common stock at a price of $4.82 per share.
- Concurrently, Peters sold 42,500 shares at $15.07, 147 shares at $15.51, 232 shares at $16.38, 5,351 shares at $17.74 and 3,165 shares at $18.22.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023.
- Following these transactions, Peters directly owns 8,895 shares of MacroGenics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives, aligning management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a common mechanism for insiders to sell shares without raising concerns about trading on non-public information; many companies such as Amgen, Regeneron, and Gilead use similar plans.
- The reported transactions are typical for executives managing their personal finances and diversifying their investment portfolios.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/08/2023 | Date of adoption of Rule 10b5-1 trading plan. |
| 02/15/2023 | Date of grant for employee stock option. |
| 04/04/2024 | Date of stock option exercise and sales. |
| 04/08/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.